FMP
Exscientia plc
EXAI
NASDAQ
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
4.01 USD
0.015 (0.375%)
About
ceo
Dr. David Hallett Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.exscientia.ai
exchange
NASDAQ
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
CIK
0001865408
ISIN
US30223G1022
CUSIP
30223G102
Address
The SchrOedinger Building
Phone
44 18 6581 8941
Country
GB
Employee
483
IPO Date
Oct 1, 2021
Key Executives
